42 completed. 42 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 42 | Completed 42 |
| Phase 2 | 5 | Completed 5 |
Follow Amyloidosis: new trials by email Literature Review of Amyloidosis trials Research Report on Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis I-124 evuzamitide - Cardiac Amyloidosis | Phase 3 | Completed | Sharmila Dorbala | 204 | 2025-01-14 | 2026-04-30 |
| Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis [18F]florbetaben - Cardiac Amyloidosis, AL Amyloidosis | Phase 3 | Completed | Lantheus Germany GmbH | 244 | 2023-01-13 | 2026-10-26 |
| CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) Eplontersen, Placebo - Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 1438 | 2020-03-13 | 2026-09-03 |
| NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Inotersen, Eplontersen - Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 168 | 2019-12-11 | 2024-12-13 |
| APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) Placebo, Patisiran - Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 | Completed | Alnylam Pharmaceuticals | 360 | 2019-09-04 | 2026-04-20 |
| Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant Patisiran - Amyloidosis, Familial, Transthyretin Amyloidosis | Phase 3 | Completed | Alnylam Pharmaceuticals | 24 | 2019-03-27 | 2024-04-22 |
| Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy acoramidis, Placebo Oral Tablet - Amyloidosis, Amyloid Cardiomyopathy | Phase 3 | Completed | Eidos Therapeutics, a BridgeBio company | 632 | 2019-03-19 | 2024-06-27 |
| Frontline Lenalidomide for AL Amyloidosis Involving Myocardium Lenalidomide 25mg - Amyloidosis Cardiac | Phase 3 | Completed | Seoul National University Hospital | 2 | 2019-02-20 | 2024-04-17 |
| HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) Patisiran, Vutrisiran - Amyloidosis, Hereditary, Transthyretin Amyloidosis | Phase 3 | Completed | Alnylam Pharmaceuticals | 164 | 2019-02-14 | 2026-01-12 |
| A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis Cyclophosphamide, Bortezomib, Dexamethasone, 40 mg - Amyloidosis | Phase 3 | Completed | Janssen Research & Development, LLC | 416 | 2017-10-05 | 2025-11-26 |
| Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy Tafamidis - Transthyretin (TTR) Amyloid Cardiomyopathy | Phase 3 | Completed | Pfizer | 1733 | 2016-06-13 | 2025-02-03 |
| The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) Patisiran - Amyloidosis | Phase 3 | Completed | Alnylam Pharmaceuticals | 211 | 2015-07-16 | 2023-12-06 |
| ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl) - Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary | Phase 3 | Completed | Alnylam Pharmaceuticals | 206 | 2014-12-01 | 2018-07-18 |
| Application of Amyloid PET in Cerebral Amyloid Angiopathy amyloid PET - Cerebral Amyloid Angiopathy, Intracranial Hemorrhages | Phase 3 | Completed | National Taiwan University Hospital | 160 | 2014-09-11 | 2019-05-30 |
| Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) Inotersen - FAP, Familial Amyloid Polyneuropathy | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 135 | 2014-06-26 | 2023-11-18 |
| Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy Tafamidis, Placebo - Transthyretin (TTR) Amyloid Cardiomyopathy | Phase 3 | Completed | Pfizer | 441 | 2013-12-09 | 2019-04-24 |
| APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl) - TTR-mediated Amyloidosis, Amyloidosis, Hereditary | Phase 3 | Completed | Alnylam Pharmaceuticals | 225 | 2013-11-01 | 2024-04-22 |
| Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy Inotersen, Placebo - FAP, Familial Amyloid Polyneuropathy | Phase 2 / Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 173 | 2013-03-15 | 2019-07-17 |
| A Trial for Systemic Light-chain (AL) Amyloidosis BMDex - AL Amyloidosis | Phase 3 | Completed | European Myeloma Network B.V. | 110 | 2011-01-01 | 2017-03-10 |
| Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis KIACTA (eprodisate disodium), Placebo - Amyloidosis | Phase 3 | Completed | C.T. Development America, Inc. | 261 | 2010-11-01 | 2016-03-10 |
Showing 20 of 42. Sign in to see all of them.
Immunoglobulin Light-chain Amyloidosis (19) · Amyloid Neuropathies, Familial (14) · Multiple Myeloma (14) · Hodgkin Disease (12) · Immunoblastic Lymphadenopathy (12) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Lymphoma, Follicular (12) · Lymphoma, Large B-Cell, Diffuse (12) · Lymphoma, Large-Cell, Anaplastic (12) · Lymphoma, Large-Cell, Immunoblastic (12) · Lymphoma, Mantle-Cell (12) · Lymphoma, Non-Hodgkin (12) · Lymphoma, T-Cell, Cutaneous (12) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (12)
Metabolic Diseases (42) · Nutritional and Metabolic Diseases (42) · Proteostasis Deficiencies (42) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (23) · Cardiovascular Diseases (20) · Immune System Diseases (20) · Genetic Diseases, Inborn (19) · Immunoproliferative Disorders (19) · Neoplasms by Histologic Type (19) · Nervous System Diseases (19) · Paraproteinemias (19) · Neoplasms (17) · Metabolism, Inborn Errors (16) · Neurodegenerative Diseases (15)
Melphalan (6) · Dexamethasone (5) · patisiran (5) · tafamidis (5) · Bortezomib (3) · Filgrastim (3) · Inotersen (3) · Darbepoetin alfa (2) · Early Intervention, Educational (2) · eplontersen (2) · liposomal amphotericin B (2) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · Asian ginseng (1) · Calcium Dobesilate (1) · Caspofungin (1)
Alnylam Pharmaceuticals (6) · Pfizer (5) · Ionis Pharmaceuticals, Inc. (4) · Alliance for Clinical Trials in Oncology (2) · Jonsson Comprehensive Cancer Center (2) · Mayo Clinic (2) · Memorial Sloan Kettering Cancer Center (2) · Bellus Health Inc. - a GSK company (1) · Boston University (1) · C.T. Development America, Inc. (1) · Case Comprehensive Cancer Center (1) · Eidos Therapeutics, a BridgeBio company (1) · European Myeloma Network B.V. (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · INSYS Therapeutics Inc (1)
United States (33) · France (19) · Italy (19) · Spain (18) · United Kingdom (18) · Germany (17) · Sweden (16) · Brazil (14) · Portugal (13) · Argentina (11) · Canada (11) · Netherlands (11) · Belgium (10) · Australia (9) · Japan (9)
Jeff Packman (2) · John A. Glaspy, MD, MPH (2) · Andrew Stephens, MD, PhD (1) · Angela Dispenzieri, M.D. (1) · Ann Traynor, MD (1) · Arnaud Jaccard, MD (1) · Charles L. Loprinzi, MD (1) · David J. Straus, MD (1) · Debra Barton, RN, PhD, AOCN, FAAN (1) · Eduardo Bruera, MD (1) · Jared Gollob (1)
PMID 38065307, PMID 27494299, PMID 30558645, PMID 31353964, PMID 32107748, PMID 32524297, PMID 33070419, PMID 34355354, PMID 34923848, PMID 35799473, PMID 36715498, PMID 37434378, PMID 37943223, PMID 38548524, PMID 38932583, PMID 40488446, PMID 41913562, PMID 41937511, PMID 42658466, PMID 15459300, PMID 16710026, PMID 17397698, PMID 17554116, PMID 17855669, PMID 20085941, PMID 22480131, PMID 23974642, PMID 24368466, PMID 24386911, PMID 26700120, PMID 26700123, PMID 27020837, PMID 28393570, PMID 28611125, PMID 28893208, PMID 29115008, PMID 29972753, PMID 29972757, PMID 30145929, PMID 30169969, PMID 30219500, PMID 30586695, PMID 30878017, PMID 31322739, PMID 31853709, PMID 32062791, PMID 32244252, PMID 32343462, PMID 32654156, PMID 32654212
2018 (3), 2019 (3), 2016 (2), P30CA015083 (2), 2014 (1), 2023 (1), P30CA068485 (1), R01CA127655 (1), R01NS051306 (1), U10CA021115 (1)